Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's disease or Lewy Body Dementia; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and orphan indications; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. The company was founded in 2016 and is headquartered in New York, New York.
Read More
